These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36048531)

  • 1. Residual Disease After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 2: Network Meta-analysis Incorporating Expert Elicitation to Adjust for Publication Bias.
    Bryant A; Grayling M; Elattar A; Gajjar K; Craig D; Vale L; Naik R
    Am J Ther; 2023 Jan-Feb 01; 30(1):e56-e71. PubMed ID: 36048531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis.
    Bryant A; Johnson E; Grayling M; Hiu S; Elattar A; Gajjar K; Craig D; Vale L; Naik R
    Am J Ther; 2023 Jan-Feb 01; 30(1):e36-e55. PubMed ID: 36608071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual disease after primary surgery for advanced epithelial ovarian cancer: expert elicitation exercise to explore opinions about potential impact of publication bias in a planned systematic review and meta-analysis.
    Bryant A; Grayling M; Hiu S; Gajjar K; Johnson E; Elattar A; Vale L; Craig D; Naik R
    BMJ Open; 2022 Aug; 12(8):e060183. PubMed ID: 36038183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
    Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
    Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.
    Hiu S; Bryant A; Gajjar K; Kunonga PT; Naik R
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD007697. PubMed ID: 36041232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical cytoreduction for recurrent epithelial ovarian cancer.
    Al Rawahi T; Lopes AD; Bristow RE; Bryant A; Elattar A; Chattopadhyay S; Galaal K
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD008765. PubMed ID: 23450588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fully Bayesian application of the Copas selection model for publication bias extended to network meta-analysis.
    Mavridis D; Sutton A; Cipriani A; Salanti G
    Stat Med; 2013 Jan; 32(1):51-66. PubMed ID: 22806991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery.
    Sørensen SM; Schnack TH; Høgdall C
    Acta Obstet Gynecol Scand; 2019 Jan; 98(1):34-43. PubMed ID: 30168853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
    Coleridge SL; Bryant A; Kehoe S; Morrison J
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD005343. PubMed ID: 33543776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
    Coleridge SL; Bryant A; Kehoe S; Morrison J
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer.
    Ngoi NY; Syn NL; Goh RM; Goh BC; Huang RY; Soon YY; James E; Cook A; Clamp A; Tan DS
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD012007. PubMed ID: 35188221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.
    Pierre ME; Manneh R; Hernández A; Rodríguez J; Fletcher AV; Ramírez HM; Niño OM; Gómez DA; Sanabria D; Contreras F; Pieschacón JR; Calderón PH
    Rev Colomb Obstet Ginecol; 2024 Jun; 75(1):. PubMed ID: 39013199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study.
    Said SA; van der Aa MA; Veldmate G; de Hullu JA; van Altena AM
    Acta Obstet Gynecol Scand; 2022 Jan; 101(1):56-67. PubMed ID: 34719790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
    Coleridge SL; Bryant A; Lyons TJ; Goodall RJ; Kehoe S; Morrison J
    Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4.
    Lof P; van de Vrie R; Korse CM; van Driel WJ; van Gent MDJM; Karlsen MA; Amant F; Lok CAR
    Int J Gynecol Cancer; 2019 Oct; 29(8):1304-1310. PubMed ID: 31515411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.